{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T08:03:21Z","timestamp":1789632201064,"version":"build-2803163510"},"reference-count":56,"publisher":"Spandidos Publications","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Lett"],"DOI":"10.3892\/ol.2026.15843","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T11:27:06Z","timestamp":1788348426000},"page":"1-15","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of rituximab in the treatment of primary central nervous system lymphoma: A meta\u2011analysis and systematic review of 1,388 patients"],"prefix":"10.3892","volume":"32","author":[{"given":"Lichaoyue","family":"Sun","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Aerospace Center Hospital, Beijing 100049, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenshu","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Emergency General Hospital, Beijing 100028, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunxing","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Aerospace Center Hospital, Beijing 100049, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhao","family":"Ren","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Aerospace Center Hospital, Beijing 100049, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Aerospace Center Hospital, Beijing 100049, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongxiao","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Aerospace Center Hospital, Beijing 100049, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2026,9,2]]},"reference":[{"key":"key20260917101351_b1-ol-32-4-15843","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/s41572-023-00439-0","article-title":"Primary central nervous system lymphoma","volume":"9","author":"Ferreri","year":"2023","journal-title":"Nat Rev Dis Primers"},{"key":"key20260917101351_b2-ol-32-4-15843","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.ejca.2019.05.024","article-title":"Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: Final analysis of the phase II \u2018proof-of-concept\u2019 iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network","volume":"117","author":"Soussain","year":"2019","journal-title":"Eur J Cancer"},{"key":"key20260917101351_b3-ol-32-4-15843","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1182\/blood.2020008377","article-title":"Primary central nervous system lymphoma","volume":"140","author":"Schaff","year":"2022","journal-title":"Blood"},{"key":"key20260917101351_b4-ol-32-4-15843","doi-asserted-by":"publisher","first-page":"5034","DOI":"10.1200\/JCO.2005.13.524","article-title":"Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma","volume":"23","author":"Abrey","year":"2005","journal-title":"J Clin Oncol"},{"key":"key20260917101351_b5-ol-32-4-15843","doi-asserted-by":"publisher","first-page":"2906","DOI":"10.1007\/s00415-023-12143-w","article-title":"Primary central nervous system lymphoma","volume":"27","author":"de Koning","year":"2024","journal-title":"J Neurol"},{"key":"key20260917101351_b6-ol-32-4-15843","doi-asserted-by":"publisher","first-page":"2410","DOI":"10.1200\/JCO.2017.72.7602","article-title":"Primary CNS lymphoma","volume":"35","author":"Grommes","year":"2017","journal-title":"J Clin Oncol"},{"key":"key20260917101351_b7-ol-32-4-15843","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1093\/neuonc\/now033","article-title":"Primary CNS lymphoma at first relapse\/progression: Characteristics, management, and outcome of 256 patients from the French LOC network","volume":"18","author":"Langner-Lemercier","year":"2016","journal-title":"Neuro Oncol"},{"key":"key20260917101351_b8-ol-32-4-15843","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1093\/jnci\/djt165","article-title":"Fifteenth biannual report of the Cochrane Haematological Malignancies Group-focus on non-Hodgkin's lymphoma","volume":"105","author":"Rancea","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"key20260917101351_b9-ol-32-4-15843","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1182\/blood-2002-06-1636","article-title":"Rituximab therapy for CNS lymphomas: Targeting the leptomeningeal compartment","volume":"101","author":"Rubenstein","year":"2003","journal-title":"Blood"},{"key":"key20260917101351_b10-ol-32-4-15843","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1093\/neuonc\/noab021","article-title":"Neurocognitive functioning and radiologic changes in primary CNS lymphoma patients: Results from the HOVON 105\/ALLG NHL 24 randomized controlled trial","volume":"23","author":"van der Meulen","year":"2021","journal-title":"Neuro Oncol"},{"key":"key20260917101351_b11-ol-32-4-15843","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1038\/s41375-022-01582-5","article-title":"Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial","volume":"36","author":"Ferreri","year":"2022","journal-title":"Leukemia"},{"key":"key20260917101351_b12-ol-32-4-15843","doi-asserted-by":"publisher","first-page":"e710","DOI":"10.1212\/WNL.0000000000207490","article-title":"Long-term outcomes in primary CNS lymphoma after R-MVP and High-dose chemotherapy with autologous hematopoietic stem cell transplant","volume":"101","author":"Therkelsen","year":"2023","journal-title":"Neurology"},{"key":"key20260917101351_b13-ol-32-4-15843","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1093\/neuonc\/noac196","article-title":"European Association of Neuro Oncology (EANO) guidelines for treatment of primary central nervous system lymphoma (PCNSL)","volume":"25","author":"Hoang-Xuan","year":"2023","journal-title":"Neuro Oncol"},{"key":"key20260917101351_b14-ol-32-4-15843","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1002\/hon.2666","article-title":"Rituximab in primary central nervous system lymphoma-A systematic review and meta-analysis","volume":"37","author":"Schmitt","year":"2019","journal-title":"Hematol Oncol"},{"key":"key20260917101351_b15-ol-32-4-15843","doi-asserted-by":"publisher","first-page":"i157","DOI":"10.1136\/bmj.i157","article-title":"PRISMA harms checklist: Improving harms reporting in systematic reviews","volume":"352","author":"Zorzela","year":"2016","journal-title":"BMJ"},{"key":"key20260917101351_b16-ol-32-4-15843","doi-asserted-by":"publisher","first-page":"111704","DOI":"10.1016\/j.jclinepi.2025.111704","article-title":"Supplementary databases increased literature search coverage beyond PubMed and Embase","volume":"181","author":"Frandsen","year":"2025","journal-title":"J Clin Epidemiol"},{"key":"key20260917101351_b17-ol-32-4-15843","doi-asserted-by":"publisher","first-page":"1538969","DOI":"10.3389\/fimmu.2025.1538969","article-title":"Assessing the impact of probiotics on immunotherapy effectiveness and antibiotic-mediated resistance in cancer: A systematic review and meta-analysis","volume":"16","author":"Zhao","year":"2025","journal-title":"Front Immunol"},{"key":"key20260917101351_b18-ol-32-4-15843","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"key":"key20260917101351_b19-ol-32-4-15843","first-page":"14","article-title":"The therapeutic effect of high-dose methotrexate (HD-MTX) with rituximab in newly diagnosed primary central nervous system lymphoma (PCNSL)","volume":"46","author":"Dina","year":"2019","journal-title":"Fudan Univ J Med Sci"},{"key":"key20260917101351_b20-ol-32-4-15843","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"key20260917101351_b21-ol-32-4-15843","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang","year":"2010","journal-title":"Eur J Epidemiol"},{"key":"key20260917101351_b22-ol-32-4-15843","doi-asserted-by":"publisher","first-page":"i6460","DOI":"10.1136\/bmj.i6460","article-title":"A guide to systematic review and meta-analysis of prediction model performance","volume":"356","author":"Debray","year":"2017","journal-title":"BMJ"},{"key":"key20260917101351_b23-ol-32-4-15843","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s00277-022-05018-z","article-title":"Performance status, comorbidities, and cycles of methotrexate exert the greatest influence on outcomes of primary and secondary CNS lymphomas: The Lexington experience","volume":"102","author":"Curry","year":"2023","journal-title":"Ann Hematol"},{"key":"key20260917101351_b24-ol-32-4-15843","first-page":"CD009355","article-title":"Role of chemotherapy additional to high-dose methotrexate for primary central nervous system lymphoma (PCNSL)","volume":"11","author":"Bergner","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"key20260917101351_b25-ol-32-4-15843","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1111\/bjh.12938","article-title":"Progress in central nervous system lymphomas","volume":"166","author":"Wang","year":"2014","journal-title":"Br J Haematol"},{"key":"key20260917101351_b26-ol-32-4-15843","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1093\/neuonc\/noab020","article-title":"Consensus recommendations for MRI and PET imaging of primary central nervous system lymphoma: Guideline statement from the International Primary CNS Lymphoma Collaborative Group (IPCG)","volume":"23","author":"Barajas","year":"2021","journal-title":"Neuro Oncol"},{"key":"key20260917101351_b27-ol-32-4-15843","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1158\/1078-0432.CCR-10-1161","article-title":"Primary CNS lymphoma in children and adolescents: a descriptive analysis from the International Primary CNS Lymphoma Collaborative Group (IPCG)","volume":"17","author":"Abla","year":"2011","journal-title":"Clin Cancer Res"},{"key":"key20260917101351_b28-ol-32-4-15843","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/S1470-2045(18)30747-2","article-title":"Rituximab in patients with primary CNS lymphoma (HOVON 105\/ALLG NHL 24): A randomised, open-label, phase 3 intergroup study","volume":"20","author":"Bromberg","year":"2019","journal-title":"Lancet Oncol"},{"key":"key20260917101351_b29-ol-32-4-15843","first-page":"444","article-title":"Clinical therapeutic efficacy of rituximab combined with methotrexate on primary central nervous system lymphoma","volume":"24","author":"Luo","year":"2016","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"key20260917101351_b30-ol-32-4-15843","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1002\/cam4.1906","article-title":"High-dose Methotrexate plus temozolomide with or without rituximab in patients with untreated primary central nervous system lymphoma: A retrospective study from China","volume":"8","author":"Chen","year":"2019","journal-title":"Cancer Med"},{"key":"key20260917101351_b31-ol-32-4-15843","first-page":"1406","article-title":"Curative efficacy of high dose MTX combined with rituxan for treatment primary CNS lymphoma","volume":"25","author":"Mou","year":"2017","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"key20260917101351_b32-ol-32-4-15843","doi-asserted-by":"publisher","first-page":"49156","DOI":"10.18632\/oncotarget.17101","article-title":"Methotrexate-cytarabine-dexamethasone combination chemotherapy with or without rituximab in patients with primary central nervous system lymphoma","volume":"8","author":"Sun","year":"2017","journal-title":"Oncotarget"},{"key":"key20260917101351_b33-ol-32-4-15843","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/JGO.18.00124","article-title":"Primary CNS Lymphoma in India: A 17-year experience from the all India institute of medical sciences","volume":"5","author":"Patekar","year":"2019","journal-title":"J Global Oncol"},{"key":"key20260917101351_b34-ol-32-4-15843","first-page":"1175","article-title":"Clinical Efficacy of High Dose Methotrexate, Temozolomide and Rituximab in the Treatment of Patients with Primary Central Nervous System Lymphoma","volume":"29","author":"Pang","year":"2021","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"key20260917101351_b35-ol-32-4-15843","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s11060-012-0891-7","article-title":"Rituximab significantly improves complete response rate in patients with primary CNS lymphoma","volume":"109","author":"Birnbaum","year":"2012","journal-title":"J Neuro Oncol"},{"key":"key20260917101351_b36-ol-32-4-15843","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1093\/neuonc\/not032","article-title":"Rituximab is associated with improved survival for aggressive B cell CNS lymphoma","volume":"15","author":"Gregory","year":"2013","journal-title":"Neuro Oncol"},{"key":"key20260917101351_b37-ol-32-4-15843","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s11060-017-2435-7","article-title":"Rituximab, methotrexate, procarbazine, vincristine and intensified cytarabine consolidation for primary central nervous system lymphoma (PCNSL) in the elderly: A LOC network study","volume":"133","author":"Houillier","year":"2017","journal-title":"J Neuro Oncol"},{"key":"key20260917101351_b38-ol-32-4-15843","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1002\/ajh.24204","article-title":"Rituximab with high-dose methotrexate in primary central nervous system lymphoma","volume":"90","author":"Kansara","year":"2015","journal-title":"Am J Hematol"},{"key":"key20260917101351_b39-ol-32-4-15843","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1212\/WNL.0000000000000593","article-title":"High-dose methotrexate with or without rituximab in newly diagnosed primary CNS lymphoma","volume":"83","author":"Holdhoff","year":"2014","journal-title":"Neurology"},{"key":"key20260917101351_b40-ol-32-4-15843","doi-asserted-by":"publisher","first-page":"2777","DOI":"10.3109\/10428194.2016.1167203","article-title":"Role of rituximab in treatment of patients with primary central nervous system lymphoma: A retrospective analysis of the Czech lymphoma study group registry","volume":"57","author":"Mocikova","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"key20260917101351_b41-ol-32-4-15843","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.annonc.2022.11.002","article-title":"Molecular and clinical diversity in primary central nervous system lymphoma","volume":"34","author":"Hern\u00e1ndez-Verdin","year":"2023","journal-title":"Ann Oncol"},{"key":"key20260917101351_b42-ol-32-4-15843","doi-asserted-by":"publisher","first-page":"v1","DOI":"10.1093\/neuonc\/now207","article-title":"CBTRUS statistical report: Primary brain and other central nervous system tumors diagnosed in the united states in 2009\u20132013","volume":"18","author":"Ostrom","year":"2016","journal-title":"Neuro Oncol"},{"key":"key20260917101351_b43-ol-32-4-15843","doi-asserted-by":"publisher","first-page":"926289","DOI":"10.3389\/fonc.2022.926289","article-title":"Relevance of Fc gamma receptor polymorphisms in cancer therapy with monoclonal antibodies","volume":"12","author":"Mata-Molanes","year":"2022","journal-title":"Front Oncol"},{"key":"key20260917101351_b44-ol-32-4-15843","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/s41397-023-00308-9","article-title":"Association between functional FCGR3A F158V and FCGR2A R131H polymorphisms and responsiveness to rituximab in patients with autoimmune diseases: A meta-analysis","volume":"23","author":"Lee","year":"2023","journal-title":"Pharmacogenomics J"},{"key":"key20260917101351_b45-ol-32-4-15843","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1097\/FPC.0000000000000175","article-title":"Accurate interrogation of FCGR3A rs396991 in European and Asian populations using a widely available TaqMan genotyping method","volume":"25","author":"Murphy","year":"2015","journal-title":"Pharmacogenet Genomics"},{"key":"key20260917101351_b46-ol-32-4-15843","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1002\/cpt.70354","article-title":"Population genomics insights into pharmacogenomic differentiation between east asians and europeans","volume":"120","author":"Chen","year":"2026","journal-title":"Clin Pharmacol Ther"},{"key":"key20260917101351_b47-ol-32-4-15843","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1215\/15228517-2008-103","article-title":"Racial differences in primary central nervous system lymphoma incidence and survival rates","volume":"11","author":"Pulido","year":"2009","journal-title":"Neuro Oncol"},{"key":"key20260917101351_b48-ol-32-4-15843","doi-asserted-by":"publisher","first-page":"e905","DOI":"10.1016\/j.wneu.2020.03.150","article-title":"Risk Factors for early mortality in patients with primary central nervous system lymphoma: A large-cohort retrospective study","volume":"138","author":"Zhou","year":"2020","journal-title":"World Neurosurg"},{"key":"key20260917101351_b49-ol-32-4-15843","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1111\/bjh.15661","article-title":"Guidelines for the diagnosis and management of primary central nervous system diffuse large B-cell lymphoma","volume":"184","author":"Fox","year":"2019","journal-title":"Br J Haematol"},{"key":"key20260917101351_b50-ol-32-4-15843","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1007\/s12185-017-2316-z","article-title":"Effect of rituximab on primary central nervous system lymphoma: A meta-analysis","volume":"106","author":"Song","year":"2017","journal-title":"Int J Hematol"},{"key":"key20260917101351_b51-ol-32-4-15843","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.clml.2023.06.008","article-title":"Role of rituximab in treatment of patients with primary central nervous system lymphoma (PCNSL): A systematic review and meta-analysis","volume":"23","author":"Zhang","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"key20260917101351_b52-ol-32-4-15843","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1093\/jjco\/hyx095","article-title":"Immunochemotherapy using rituximab (RTX) and high-dose methotrexate (HD-MTX): An evaluation of the addition of RTX to HD-MTX in recurrent primary central nervous system lymphoma (PCNSL)","volume":"47","author":"Miyakita","year":"2017","journal-title":"Jpn J Clin Oncol"},{"key":"key20260917101351_b53-ol-32-4-15843","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1182\/bloodadvances.2022008525","article-title":"Toxicity and efficacy of CAR T-cell therapy in primary and secondary CNS lymphoma: A meta-analysis of 128 patients","volume":"7","author":"Cook","year":"2023","journal-title":"Blood Adv"},{"key":"key20260917101351_b54-ol-32-4-15843","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.mcna.2022.12.008","article-title":"Drug-induced liver injury due to biologics and immune check point inhibitors","volume":"107","author":"Bessone","year":"2023","journal-title":"Med Clin North Am"},{"key":"key20260917101351_b55-ol-32-4-15843","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1053\/j.gastro.2014.10.039","article-title":"American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy","volume":"148","author":"Reddy","year":"2015","journal-title":"Gastroenterology"},{"key":"key20260917101351_b56-ol-32-4-15843","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.anai.2023.01.018","article-title":"Hypogammaglobulinemia, late-onset neutropenia, and infections following rituximab","volume":"130","author":"Athni","year":"2023","journal-title":"Ann Allergy Asthma Immunol"}],"container-title":["Oncology Letters"],"original-title":[],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T07:15:02Z","timestamp":1789629302000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ol.2026.15843"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,2]]},"references-count":56,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,9,2]]}},"URL":"https:\/\/doi.org\/10.3892\/ol.2026.15843","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,2]]}}}